Skip to content
drillr.ai
Sign up

600521.SH

华海药业

SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN

CNY 16.20
−2.53%
Ask drillr

  • Aug 26, 2026, 10:52 UTC

    Huahai Pharmaceutical reported its first-half 2026 results, with net profit attributable to shareholders of 771 million yuan, up 88.26% year-on-year.

    Source:

  • Aug 19, 2026, 09:46 UTC

    Huahai Pharmaceutical announced that three subsidiaries passed drug GMP compliance inspections, covering products including the IL-36R monoclonal antibody and an API.

    Source:

  • Aug 8, 2026, 13:44 UTC

    Multiple Chinese A-share listed companies announced they received tariff refunds from the U.S. Customs and Border Protection, including Guizhou Tyre, Dongjian Technology, Kaineng Health, Honghe Technology, and Huahai Pharmaceutical.

    Source:

  • Aug 2, 2026, 07:49 UTC

    Huahai Pharmaceutical participated in the bidding for the 12th national centralized drug procurement on July 31, 2026, and its four products—lamotrigine tablets, iguratimod tablets, perindopril amlodipine tablets (III), and mesalazine enteric-coated tablets—were provisionally selected, with the procurement period running from the execution date of the selection results to December 31, 2029.

    Source:

  • Jul 27, 2026, 01:51 UTC

    Jinhua State-owned Assets acquired control of Baihua Pharmaceutical for 887 million yuan.

    Source:

  • Jul 24, 2026, 09:26 UTC

    Huahai Pharmaceutical's subsidiaries Hua'ao Tai and Huabo Bio received a clinical trial approval notice from the National Medical Products Administration for the injection HB0043 with a new subcutaneous administration route for hidradenitis suppurativa.

    Source:

  • Jul 23, 2026, 09:46 UTC

    Huahai Pharmaceutical received a drug registration certificate from the National Medical Products Administration for its ferrous succinate tablets, used for the prevention and treatment of iron deficiency anemia.

    Source:

  • Jul 15, 2026, 10:55 UTC

    Huahai Pharmaceutical appointed Xu Xuejian as Vice President and Chief Quality Officer.

    Source:

  • Jul 10, 2026, 10:02 UTC

    Huahai Pharmaceutical and its subsidiaries had 54 products (79 specifications) included in the National Essential Drug List (2026 edition), with 23 products (33 specifications) newly added.

    Source:

  • Jul 2, 2026, 09:45 UTC

    Zhejiang Huahai Pharmaceutical Co., Ltd. received a Drug Registration Certificate from the National Medical Products Administration for its metaraminol bitartrate injection, a new product launch.

    Source: